Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants with relapsing multiple sclerosis (STRIVE-MS)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: df2fffcadb03dd73b530a0f7c3ca221e5a0910eb
First added on: Jan 17, 2026